Hemophilia was recognized long before anyone understood what caused it. References to families plagued by uncontrollable bleeding appear in ancient Jewish texts from as early as the second century, but the first systematic clinical description did not arrive until 1803, when a Philadelphia physician named John Conrad Otto published an account of a New Hampshire family whose male members bled profusely from trivial injuries. From that point, progress came in waves: a name for the disease in the 1820s, its most famous carrier in the 1830s, a biochemical explanation in the mid-twentieth century, and the first treatments that actually worked a decade or two later. The story of hemophilia’s discovery is really the story of centuries of observation gradually catching up with science.
Early Observations of Familial Bleeding
People noticed the pattern long before they could explain it. The Babylonian Talmud, compiled around the second century CE, contains rabbinical rulings that excused boys from circumcision if their older brothers had bled to death from the procedure. The rule extended to sons of sisters whose own sons had died the same way, which amounts to an intuitive grasp of the maternal inheritance pattern without any concept of genetics. Similar scattered observations appeared in Arabic medical writings during the medieval period. None of these sources used a single disease name or attempted a physiological explanation, but they clearly described a condition that ran in families and struck boys far more than girls.
John Conrad Otto and the First Clinical Description
The leap from folk observation to medical documentation happened in 1803, when John Conrad Otto, a physician at the Pennsylvania Hospital in Philadelphia, published an article in the Medical Repository. Otto described a family named Smith, from the area around Plymouth, New Hampshire, whose male members were what he called “bleeders.” He traced the condition through several generations and noted that women transmitted the trait without being affected themselves. This was the first definitive account of hemophilia to reach physicians in America and Europe, though descriptions of familial bleeders existed in much older writings.1JAMA. JOHN CONRAD OTTO (1774-1844) KINDLY PHYSICIAN
Otto did not coin the word “hemophilia.” That came later, in the 1820s, when the German physician Johann Lukas Schönlein began using the term to describe the condition Otto and others had documented.2American Journal of Diseases of Children. JOHN CONRAD OTTO 1774-1844: A NOTE ON THE HISTORY OF HEMOPHILIA The word itself comes from the Greek for “love of blood,” which is slightly misleading since the problem is not that the body produces too much blood but that it cannot stop bleeding once it starts. Still, the name stuck, and by the mid-nineteenth century hemophilia was an established clinical entity in European and American medicine.
Queen Victoria and the Royal Disease
Hemophilia became famous not through medical journals but through royal genealogy. Queen Victoria of England, who reigned from 1837 to 1901, was a carrier. She passed the trait to several of her children, who married into royal families across Europe. Within a few generations, hemophilia appeared in the Spanish, German, and Russian royal houses. The political consequences were enormous: the most dramatic case involved Tsarevich Alexei, the only son of Tsar Nicholas II of Russia, whose severe bleeding episodes gave the mystic Rasputin his foothold in the court, a chain of events that many historians link to the instability preceding the Bolshevik Revolution.3PubMed. The ‘royal disease’–haemophilia A or B? A haematological mystery is finally solved
For over a century, nobody knew exactly which type of hemophilia Victoria carried. That mystery was not resolved until 2009, when researchers applied modern genomic techniques to bone fragments from the Romanov family remains. They identified a mutation in the F9 gene on the X chromosome, which encodes coagulation factor IX. The mutation was predicted to alter how the gene’s instructions are read, producing a truncated and nonfunctional version of the protein. This meant the royal disease was hemophilia B, also known as Christmas disease, rather than the more common hemophilia A.4PubMed. Genotype analysis identifies the cause of the “royal disease”
Victoria’s mutation likely arose spontaneously. Neither of her parents showed signs of hemophilia, and no earlier ancestors on either side had documented bleeding problems. Spontaneous mutations account for roughly a third of all new hemophilia cases, which is why the disease never disappears from a population even though severely affected males historically died young.
Separating Hemophilia A from Hemophilia B
Until the 1940s and 1950s, all cases of hemophilia were lumped together as one disease. That changed in 1952, when a group of British researchers demonstrated that blood from certain hemophilia patients could actually correct the clotting defect in other hemophilia patients when mixed together. If all patients were missing the same thing, mixing their blood should not have helped. The fact that it did meant at least two different clotting factors were involved. The newly identified form was named Christmas disease after Stephen Christmas, one of the first patients described in the study, and the deficient protein became known as factor IX, or Christmas factor.5PubMed. Christmas disease: a condition previously mistaken for haemophilia
The original form, involving a deficiency in factor VIII, became hemophilia A. Hemophilia A accounts for roughly 80 percent of all hemophilia cases, and hemophilia B accounts for most of the rest. The two are clinically indistinguishable at the bedside: both cause prolonged bleeding into joints, muscles, and soft tissues, and both follow the same X-linked inheritance pattern. The only way to tell them apart is through laboratory testing that measures specific clotting factor levels.
A third type, hemophilia C, was recognized a year later, in 1953, after patients experienced severe bleeding following dental extractions. It involves a deficiency of factor XI and follows a different inheritance pattern, affecting both men and women. It is far rarer than the other two types, with an estimated prevalence of about one in a million in the general population, though it is considerably more common among Ashkenazi Jews, where the prevalence has been reported as high as 8 percent in Israel.6PubMed Central. Hemophilia C: A Case Report With Updates on Diagnosis and Management of a Rare Bleeding Disorder
From Whole Blood to Cryoprecipitate
For most of hemophilia’s documented history, there was no effective treatment. Physicians tried bed rest, pressure, and various folk remedies. Whole blood transfusions offered some benefit, but the amount of clotting factor delivered in a unit of whole blood was too low to manage serious bleeds reliably. In the early twentieth century, the development of plasma transfusions was a step forward, since plasma contained higher concentrations of clotting factors than whole blood, but patients still needed large volumes, and the treatment was hospital-based and cumbersome.
The real breakthrough came in 1964, when Judith Graham Pool, a researcher at Stanford, discovered that slowly thawing frozen plasma produced a cold-insoluble precipitate rich in factor VIII. This cryoprecipitate could be separated, concentrated, and stored. A single bag of cryoprecipitate contained far more factor VIII than an equivalent volume of fresh plasma, making it practical to treat bleeds more aggressively and, for the first time, to perform elective surgery on hemophilia patients with some confidence.7PubMed. Judith Graham Pool and the discovery of cryoprecipitate
Pool’s discovery is often cited as the single most important advance in hemophilia treatment before the era of recombinant products. It was simple, relatively inexpensive, and could be prepared at any blood bank. For the first time, people with hemophilia had a realistic shot at managing their condition outside a hospital setting.
Commercial Factor Concentrates and the Blood Contamination Crisis
By the 1970s, pharmaceutical companies had developed lyophilized (freeze-dried) factor concentrates that could be stored at room temperature and reconstituted with sterile water. This was transformative. Patients could keep vials at home, mix the product themselves, and infuse it intravenously at the first sign of a bleed. Home therapy changed the daily reality of hemophilia: children could attend school more regularly, adults could hold jobs, and joint damage from untreated bleeds became less inevitable.8PubMed. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy
But those concentrates were manufactured by pooling plasma from thousands of donors, and no reliable methods existed to screen for or inactivate blood-borne viruses. When HIV and hepatitis C entered the blood supply, the concentrates became extraordinarily efficient vehicles for transmission. A high percentage of people with hemophilia who used plasma-derived concentrates during the late 1970s and 1980s became infected with HIV, hepatitis C, or both.9PubMed Central. Hemophilia: An Amazing 35-Year Journey from the Depths of HIV to the Threshold of Cure Hepatitis C virus was the most frequently detected contaminant in tested batches of factor VIII and IX concentrates from that era, with extremely high viral loads found in products manufactured between the late 1970s and 1985. Detection frequencies dropped sharply after virus inactivation methods were introduced.10PubMed. Reconstruction of the historic time course of blood-borne virus contamination of clotting factor concentrates, 1974-1992
The contaminated blood crisis was a catastrophe for the hemophilia community. In the United States alone, thousands of people with hemophilia contracted HIV, and many died. The scandal prompted sweeping reforms in blood banking, donor screening, and regulatory oversight. It also accelerated the push toward products that did not depend on human plasma at all.
Recombinant Factor Products
The cloning of the factor VIII gene in the early 1980s opened the door to a fundamentally different approach: manufacturing clotting factors using recombinant DNA technology in laboratory cell lines rather than extracting them from donated plasma.11PubMed Central. Advancements in gene transfer-based therapy for hemophilia A The first recombinant factor VIII product reached the market in the early 1990s, and recombinant factor IX followed soon after.8PubMed. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy These products eliminated the risk of transmitting blood-borne infections and restored confidence in treatment that the contamination crisis had shattered.
Recombinant products also enabled routine prophylaxis, where patients infuse factor on a regular schedule to prevent bleeds rather than waiting for one to occur. Prophylactic regimens, which had been introduced during the 1970s using plasma-derived products, proved far more effective at preventing joint damage than on-demand treatment.12PubMed Central. The history and evolution of the clinical effectiveness of haemophilia type a treatment: a systematic review With recombinant products, prophylaxis became the standard of care in high-income countries.
Dogs, Lab Models, and the Path to Human Trials
One of the less celebrated chapters in hemophilia history is the role of animals, particularly dogs. Hemophilia occurs naturally in several dog breeds, and colonies of hemophilic dogs have been maintained at research institutions for decades. These dogs bleed severely, just like humans with the same condition, and for nearly seven decades they have served as testing grounds for everything from basic clotting assays to novel gene therapies.13PubMed. Canine models of inherited bleeding disorders in the development of coagulation assays, novel protein replacement and gene therapies
The first reliable diagnostic assays for hemophilia were developed in the 1940s through research on these dogs. Later, canine models became essential for preclinical testing of factor replacement products. Research has consistently shown that replacement products found to be safe and effective in hemophilic dogs prove safe and effective in humans as well, making these animals remarkably predictive models.14ILAR Journal. Protein Replacement Therapy and Gene Transfer in Canine Models of Hemophilia A, Hemophilia B, von Willebrand Disease, and Factor VII Deficiency Gene therapy trials, which carry unique safety concerns like the possibility of a viral vector inserting itself in the wrong place in the genome, have relied heavily on dogs to establish dose ranges before moving to human volunteers.15PubMed Central. Animal models of hemophilia and related bleeding disorders
The Inhibitor Problem
As treatment improved, a new complication emerged. Some patients’ immune systems recognized the infused clotting factor as foreign and produced antibodies against it, called inhibitors. These antibodies neutralize the replacement factor, making standard treatment ineffective. Inhibitor development is now considered the most significant complication of hemophilia treatment and is associated with considerable harm and reduced quality of life.16PubMed Central. Factor VIII inhibitors in hemophilia A: rationale and latest evidence
Inhibitors develop in roughly a quarter to a third of people with severe hemophilia A and a smaller proportion of those with hemophilia B. The risk is highest during the first exposures to factor replacement, typically in early childhood. Managing patients with inhibitors requires either immune tolerance induction therapy, which involves prolonged high-dose factor infusions to train the immune system to accept the protein, or bypassing agents that promote clotting through an alternative route. Neither approach is ideal, and the development of inhibitors drove much of the research into non-factor therapies.
Emicizumab and the Era of Non-Factor Therapies
The most significant departure from traditional factor replacement arrived with emicizumab, a bispecific antibody approved in 2017. Instead of replacing the missing factor VIII, emicizumab mimics what factor VIII does: it bridges activated factor IX and factor X, allowing the clotting cascade to proceed without factor VIII being present at all.17PubMed Central. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A Because it is an antibody rather than a clotting factor, it is not neutralized by factor VIII inhibitors, which makes it effective in patients who had previously run out of good options.
Emicizumab is also administered by subcutaneous injection rather than intravenous infusion, and its long half-life allows dosing as infrequently as once every two to four weeks. For patients accustomed to intravenous infusions several times a week, the convenience is substantial. The drug does not work for hemophilia B, since the mechanism specifically mimics factor VIII’s role, but its success has opened the door to similar approaches for other clotting deficiencies.
Gene Therapy and the Prospect of a Functional Cure
Hemophilia has been considered an ideal candidate for gene therapy almost since the concept was first proposed. It is caused by a single defective gene, the missing protein circulates in the bloodstream rather than needing to be delivered to a specific tissue, and even modest increases in clotting factor levels dramatically reduce bleeding. For nearly three decades, researchers have pursued gene transfer strategies for both hemophilia A and hemophilia B.18PubMed Central. Adeno-Associated Virus Gene Therapy for Hemophilia
The approach that has advanced furthest uses adeno-associated virus (AAV) vectors to deliver a working copy of the clotting factor gene to liver cells, where clotting factors are naturally produced. Early clinical trials for hemophilia B demonstrated that a single administration of an AAV vector could produce stable factor IX expression for up to eight years at levels high enough to reduce spontaneous bleeds and, in some patients, eliminate the need for regular factor infusions.19Thrombosis Research. How Was Hemophilia Discovered? A Look at Its History Trials for hemophilia A have also reported encouraging results, with some patients achieving clotting factor levels in the therapeutic or even curative range.20PubMed Central. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
Gene therapy is not without complications. A significant proportion of the population carries pre-existing antibodies against AAV capsids from prior natural infections, which can block the vector before it reaches the liver. Some patients have experienced rises in liver enzymes after treatment, sometimes accompanied by a decline in transgene expression. And the durability of the effect remains an open question: while some patients have maintained therapeutic factor levels for years, others have seen a gradual decline. Researchers are actively developing more efficient vectors and immunosuppressive strategies to address these issues.
How Life Expectancy Has Changed
Perhaps the starkest way to measure progress is through survival data. A study of Swedish hemophilia patients spanning 150 years found that median life expectancy for people with severe hemophilia rose from just 11 years during the period 1831 to 1920 to about 57 years during the period 1961 to 1980. For those with moderate hemophilia, the corresponding figures were roughly 28 years and 72 years. By the last twelve years of that study, death rates for severe hemophilia patients under age 45 were not dramatically different from those of Swedish men overall.21PubMed. Life expectancy of Swedish haemophiliacs, 1831-1980
The HIV crisis reversed some of those gains during the 1980s and 1990s. But the introduction of recombinant products and modern antiviral treatments restored the upward trajectory, and in high-income countries today, people with hemophilia can expect to live close to a normal lifespan.22PubMed Central. Hemophilia therapy: the future has begun. The gap between that figure and the 11-year median of a century ago captures the distance hemophilia has traveled from a mysterious and often fatal family curse to one of the most thoroughly understood and increasingly treatable genetic conditions in medicine.